Deep-Learning Based Contrast Boosting: A Multi-Center Multi-Reader Study on Clinical Performance With Standard Contrast Enhanced Brain MRI.

Srivathsa Pasumarthi Venkata¹, Thomas Campbell Arnold¹, Sonia Colombo Serra², Jeffrey D Rudie³, Jalal B Andre⁴, Ronny Elor¹, Dayang Wang¹, Praveen Gulaka¹, Ajit Sankaranarayanan¹, Gunter Erb⁵, Greg Zaharchuk⁶

¹Subtle Medical Inc., Menlo Park, California, USA.

²Global R&D, Bracco Imaging SpA, Colleretto Giacosa, Italy.

³Department of Radiology, University of California San Diego, La Jolla, California, USA.

⁴Department of Radiology, University of Washington Medicine, Seattle, Washington, USA.

⁵Global Medical & Regulatory Affairs, Bracco Imaging Deutschland GmbH, Konstanz, Germany.

⁶Department of Radiology, Stanford University, Palo Alto, California, USA.

PubMed DOI

Abstract

BACKGROUND: Gadolinium-based contrast agents are used in brain MRI to improve the visualization of disorders and improve the delineation of lesions. Higher doses of GBCAs can improve lesion sensitivity but may have safety implications, particularly in light of recent findings on gadolinium retention and deposition. PURPOSE: To evaluate the clinical performance of an FDA-cleared deep-learning (DL)…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.